Seattle Genetics and CuraGen Expand Antibody-Drug Conjugate Collaboration

Seattle Genetics has announced that CuraGen has exercised its option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration, triggering a $1 million payment to Seattle Genetics. Seattle Genetics entered into the ADC collaboration with CuraGen in June 2004, at which time CuraGen paid an upfront fee of $2 million for access to the ADC technology for one antigen target.

Yahoo News (http://biz.yahoo.com/bw/050215/155493_1.html)